TrialBreast cancer research and treatment2012

A phase II trial of capecitabine in combination with the farnesyltransferase inhibitor tipifarnib in patients with anthracycline-treated and taxane-resistant metastatic breast cancer: an Eastern Cooperative Oncology Group Study (E1103).

Tianhong Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.